Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BJU Int
    December 2026
  1. LU H, Zhang Y, Zhao Y, Zhang Y, et al
    Global trends in urological cancers: an analysis of the global burden of disease study 2023.
    BJU Int. 2026;138:1034-1042.
    >> Share

    November 2026
  2. SIMARD F, Lacombe MM, Simonyan D, Garneau CA, et al
    Beyond the label 'high-grade': histological heterogeneity as a prognostic marker in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Nov 2. doi: 10.1111/bju.70522.
    >> Share

  3. MELLE-HANNAH M, Kjolhede H, Backdahl H, Johansson ME, et al
    First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument.
    BJU Int. 2026;138:867-876.
    >> Share

  4. LEHNER F, Dugas S, Birkhauser V, Gross O, et al
    Bladder washing cytology in the initial evaluation of patients with neuro-urological disorders: to do or not to do?
    BJU Int. 2026;138:860-866.
    >> Share

  5. MUNK L, Hyldgaard JM, Kumasegaram V, Milling RV, et al
    Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial.
    BJU Int. 2026;138:831-840.
    >> Share

    October 2026
  6. DEPALMA M, Rossi F, Ferro M, Bukavina L, et al
    Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer: efficacy proven, duration unclear.
    BJU Int. 2026 Oct 21. doi: 10.1111/bju.70507.
    >> Share

  7. WANG J, Zhao Y, Ye Y, Qi X, et al
    Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.
    BJU Int. 2026 Oct 11. doi: 10.1111/bju.70488.
    >> Share

  8. ESCRIG JLD, Black P, Inokuchi J, Kulkarni G, et al
    Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.
    BJU Int. 2026 Oct 2. doi: 10.1111/bju.70480.
    >> Share

  9. CONNOR MJ, Gopalakrishnan A, Mayor N, Bolton E, et al
    Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).
    BJU Int. 2026;138:705-713.
    >> Share

  10. CONTIERI R, van Rhijn BWG, Cathomas R, Lorch A, et al
    Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
    BJU Int. 2026;138:558-564.
    >> Share

  11. GABRIEL PE, Zhu A, Karim CG, Eraky A, et al
    Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.
    BJU Int. 2026;138:640-649.
    >> Share

    September 2026
  12. TOUMAZOS K, Bell S, Spencer K, Nakagawa D, et al
    Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
    BJU Int. 2026 Sep 28. doi: 10.1111/bju.70461.
    >> Share

  13. HURLE R, Contieri R, Sormani F, Lazzeri M, et al
    Quality of life in patients on active surveillance for bladder cancer.
    BJU Int. 2026 Sep 9. doi: 10.1111/bju.70449.
    >> Share

  14. IBRAHIM Y, Ribeiro L, Spazzapan M, Gad M, et al
    Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.
    BJU Int. 2026;138:449-455.
    >> Share

    August 2026
  15. MIYAJIMA K, Miszczyk M, Roessler N, Inoue S, et al
    Diet and risk of bladder cancer: a systematic review of epidemiological evidence.
    BJU Int. 2026 Aug 23. doi: 10.1111/bju.70435.
    >> Share

  16. CELLA L, Contieri R, Paciotti M, Fasulo V, et al
    Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.
    BJU Int. 2026 Aug 17. doi: 10.1111/bju.70404.
    >> Share

  17. CHEN Y, Yue Z
    Incidence is not surveillance yield: interpreting metachronous upper tract urothelial carcinoma risk after non-muscle-invasive bladder cancer.
    BJU Int. 2026 Aug 11. doi: 10.1111/bju.70429.
    >> Share

    July 2026
  18. LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
    INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
    BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
    >> Share

  19. DUAN Q
    Letter to the Editor regarding: reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Jul 17. doi: 10.1111/bju.70385.
    >> Share

  20. GHALI F, Tan WS
    A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 3. doi: 10.1111/bju.70377.
    >> Share

  21. AYDOGDU C, Wang B, McSweeney ST, Diaz G, et al
    Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 2. doi: 10.1111/bju.70376.
    >> Share

  22. NOLAZCO JI, Melnick KR, Lee RJ, Efstathiou JA, et al
    Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.
    BJU Int. 2026;138:22-32.
    >> Share

  23. ORECCHIA L, Gerardi M, Colalillo G, Leonardis F, et al
    Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
    BJU Int. 2026;138:92-99.
    >> Share

    June 2026
  24. UROLAGIN D, Sowmya BA, Kavyashree MV
    Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 10. doi: 10.1111/bju.70296.
    >> Share

  25. VAN HATTUM JW, Remmelink MJ, Oddens JR, de Reijke TM, et al
    Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 9. doi: 10.1111/bju.70295.
    >> Share

  26. CONTIERI R, Martini A, Furrer M, D'Andrea D, et al
    Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
    BJU Int. 2026;137:1058-1066.
    >> Share

  27. DIANA P, Di Bello F, Mas L, Gallioli A, et al
    Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.
    BJU Int. 2026;137:1026-1031.
    >> Share

  28. SOPUTRO NA, Wang L, Daher K, Al-Bayati A, et al
    Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.
    BJU Int. 2026;138 Suppl 1:S49-S55.
    >> Share

    May 2026
  29. ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
    Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
    BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
    >> Share

  30. TILLU N, Wiklund P
    Response to: 'Comment on long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 11. doi: 10.1111/bju.70312.
    >> Share

  31. CHETHAN GS, Patil NS
    Comment on 'Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 7. doi: 10.1111/bju.70313.
    >> Share

    April 2026
  32. PACKIAM VT, Black PC, Catto JWF, Ghodoussipour S, et al
    'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.
    BJU Int. 2026 Apr 28. doi: 10.1111/bju.70299.
    >> Share

  33. VAN HOOGSTRATEN LMC, Vermeulen SH, Hof JP, van der Heijden AG, et al
    Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70297.
    >> Share

  34. ZHANG B, Wang C, Shang P
    Comment on 'Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach'.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70302.
    >> Share

  35. FU MZ, Packiam VT, Byrne J
    Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
    >> Share

  36. KUMAR V, Kant R
    Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
    >> Share

  37. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
    >> Share

  38. SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
    Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
    >> Share

  39. BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
    Is there still a role for ureteric frozen section analysis during radical cystectomy?
    BJU Int. 2026;137:659-666.
    >> Share

  40. DAY E, Bizzarri FP, Waine E, Martin R, et al
    Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
    BJU Int. 2026;137:708-715.
    >> Share

  41. PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
    Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
    BJU Int. 2026;137:684-689.
    >> Share

    March 2026
  42. HJORT PB, Jensen JB, Ernst A
    Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
    >> Share

  43. YE T, Tura B, Abbotts B, Zeegers MP, et al
    Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
    BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
    >> Share

  44. SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
    Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
    >> Share


  45. Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
    >> Share

  46. SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
    Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
    BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
    >> Share

  47. ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
    Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
    BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
    >> Share

  48. BRYAN RT, Patel K, Ward DG
    The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
    >> Share

  49. FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
    Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
    >> Share

  50. AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
    Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
    BJU Int. 2026;137:536-546.
    >> Share

    February 2026
  51. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
    Aligning bladder cancer research with patient needs: an update on research priorities.
    BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
    >> Share

  52. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
    Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
    >> Share

  53. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
    Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
    BJU Int. 2026;137:323-331.
    >> Share

  54. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
    Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
    BJU Int. 2026;137:270-281.
    >> Share

    January 2026
  55. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
    BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
    >> Share

  56. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
    Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
    >> Share

  57. DI BELLO F, Gallioli A, Cannoletta D, Mancon S, et al
    Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis.
    BJU Int. 2026;137:26-35.
    >> Share

  58. MIEDERER M, Pretze M, Abbate E, Hartig A, et al
    Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
    BJU Int. 2026;137:166-172.
    >> Share

    December 2025
  59. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
    Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
    >> Share

  60. MENNES J, Akand M, Benijts R, Baekelandt L, et al
    Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
    >> Share

    November 2025

  61. Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
    BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
    >> Share

  62. PACE KJC, Kwong JCC, Randhawa H, Ringa M, et al
    Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 19. doi: 10.1111/bju.70085.
    >> Share

  63. ABDULMAJEED A, Bekiroglu F, Aydin A, Laguna P, et al
    Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants.
    BJU Int. 2025 Nov 18. doi: 10.1111/bju.70079.
    >> Share

  64. RHODES AC, McClintic KA, Witt E, Nwosu I, et al
    Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 3. doi: 10.1111/bju.70060.
    >> Share

  65. BRANDT SB, Korner SK, Milling RV, Nielsen NK, et al
    Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
    BJU Int. 2025;136:858-865.
    >> Share

  66. MASTROIANNI R, Chiacchio G, Tuderti G, Brassetti A, et al
    Stapled vs totally handsewn robotic intracorporeal neobladder: perioperative and functional outcomes.
    BJU Int. 2025;136:866-871.
    >> Share

    October 2025
  67. MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al
    Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Oct 22. doi: 10.1111/bju.70044.
    >> Share

  68. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
    Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
    BJU Int. 2025;136:728-737.
    >> Share

  69. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
    BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
    >> Share

  70. PAYNTER JA, Doherty Z, Qin KR, Pilcher D, et al
    Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions.
    BJU Int. 2025;136 Suppl 2.
    >> Share

    September 2025
  71. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
    Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
    >> Share

  72. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
    Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
    BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
    >> Share

  73. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    >> Share

  74. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
    Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
    BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
    >> Share

    August 2025
  75. ZAURITO P, Scilipoti P, Longoni M, Viti A, et al
    The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
    >> Share

  76. DEY L, Rautiola J, Akre O, Egevad L, et al
    Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
    >> Share

  77. DE ANGELIS M, Scilipoti P, Santangelo A, Longoni M, et al
    The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates.
    BJU Int. 2025;136:336-343.
    >> Share

  78. BEN-DAVID R, Pellegrino F, Mehrazin R, Thomas J, et al
    Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy.
    BJU Int. 2025;136:321-328.
    >> Share

    July 2025
  79. LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al
    Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
    >> Share

  80. HOF J, Vermeulen S, Richters A
    Biased associations between number of BCG instillations and outcome in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866.
    >> Share

  81. VON DEIMLING M, Furrer M, Bianchi A, Pichler R, et al
    Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer.
    BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851.
    >> Share

  82. TEMPO J, Felemban S, Qin KR, Perera M, et al
    Radical cystectomy mortality in older patients: a systematic review and meta-analysis.
    BJU Int. 2025;136:19-31.
    >> Share

    June 2025
  83. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    >> Share

  84. FERRO M, Catellani M, Bianchi R, Fallara G, et al
    Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828.
    >> Share

  85. ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al
    Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel.
    BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827.
    >> Share

  86. HANEY CM, Studier-Fischer A, Geissler ME, Ohlmeier J, et al
    Indocyanine-guided ureter resection for radical cystectomy - a systematic review and meta-analysis.
    BJU Int. 2025;135:908-917.
    >> Share

  87. AMPARORE D, De Cillis S, Colombo M, Garzena V, et al
    TYTOCARE home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
    BJU Int. 2025;135:960-968.
    >> Share

    May 2025
  88. KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al
    Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
    BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
    >> Share

  89. VAN HATTUM JW, Remmelink MJ, Nuijens ST, de Ruiter BM, et al
    A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer.
    BJU Int. 2025 May 22. doi: 10.1111/bju.16767.
    >> Share

  90. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
    Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.
    BJU Int. 2025 May 21. doi: 10.1111/bju.16780.
    >> Share

  91. BOSVELD J, Nguyen TQ, Boormans JL, Witjes JA, et al
    The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.
    BJU Int. 2025;135:766-774.
    >> Share

    April 2025
  92. NUIJENS ST, van Hoogstraten LMC, Terpstra NB, Beeren I, et al
    The impact of treatment for muscle-invasive bladder cancer on health-related quality of life.
    BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736.
    >> Share

  93. BRYAN RT, Patel P, Kennish SJ, Catto JWF, et al
    Improving the pathway to correct treatment for patients with muscle-invasive bladder cancer: exploring the myths around the BladderPath trial.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728.
    >> Share

    March 2025
  94. COLLETT G, Bashford T, Whitehead NJ, Kazimierska E, et al
    Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army.
    BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
    >> Share

  95. TREVISANI F, Floris M, Longoni M, Rosiello G, et al
    Acute kidney disease after radical cystectomy for bladder cancer: a new onco-nephrological view.
    BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
    >> Share

  96. ROLDAN FL, Ingelmo-Torres M, Mercader C, Figueras M, et al
    Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16697.
    >> Share

  97. CHOWDHURY D, Apolo AB, Jiang DM, Skinner EC, et al
    Understanding patient perspectives in the management of their muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16695.
    >> Share

  98. RAUTIOLA J, Bjorklund J, Ben-David R, Skokic V, et al
    Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer.
    BJU Int. 2025 Mar 4. doi: 10.1111/bju.16691.
    >> Share


  99. Advances in the management of high-risk localised muscle invasive bladder cancer.
    BJU Int. 2025;135:364-365.
    >> Share

  100. STRUCK JP, Moharam N, Leitenberger A, Weber J, et al
    An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.
    BJU Int. 2025;135:446-455.
    >> Share

  101. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes.
    BJU Int. 2025;135:473-480.
    >> Share

    February 2025
  102. TILLU N, Ben-David R, Skokic V, Rich JM, et al
    Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
    >> Share

  103. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
    >> Share

    January 2025
  104. BEEREN I, Meijer H, van der Heijden AG, Aben KKH, et al
    Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
    >> Share

  105. KLUGER N, van der van der Bent SAS
    Tattoos as a risk factor for bladder cancer: a call for cohort studies.
    BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
    >> Share

  106. OLAH C, Sichward L, Hadaschik B, Darr C, et al
    Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
    >> Share

  107. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
    BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
    >> Share

  108. PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
    National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
    BJU Int. 2025;135:140-147.
    >> Share

  109. JOHN JB, Collins M, Eames S, O'Flynn K, et al
    The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
    BJU Int. 2025;135:78-87.
    >> Share

    December 2024
  110. LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
    Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
    BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
    >> Share

  111. HAILE ES, Lone Z, Shin D, Nowacki AS, et al
    Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
    >> Share

  112. PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
    International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
    BJU Int. 2024;134:932-938.
    >> Share

  113. GUO AA, Zeng K, Bushati Y, Kim P, et al
    Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
    BJU Int. 2024;134 Suppl 2:22-29.
    >> Share

  114. AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
    Long-term quality of life in patients with bladder cancer following radical cystectomy.
    BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
    >> Share

    November 2024
  115. LONE Z, Shin D, Nowacki A, Campbell RA, et al
    Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
    BJU Int. 2024;134:841-847.
    >> Share

  116. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
    A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
    BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
    >> Share

    October 2024
  117. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    >> Share

  118. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
    Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.
    BJU Int. 2024 Oct 21. doi: 10.1111/bju.16565.
    >> Share

  119. DEL GIUDICE F, Vestri A, Fegatelli DA, Husch T, et al
    VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
    BJU Int. 2024 Oct 13. doi: 10.1111/bju.16531.
    >> Share

  120. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
    Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
    BJU Int. 2024;134:541-550.
    >> Share

  121. RIEGER C, Schluchtermann J, Storz E, Kastner L, et al
    Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
    BJU Int. 2024;134:582-588.
    >> Share

    September 2024
  122. CONROY S, Jubber I, Noon AP, Rosario DJ, et al
    Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
    BJU Int. 2024 Sep 26. doi: 10.1111/bju.16516.
    >> Share

  123. LIU K, Nicoletti R, Zhao H, Chen X, et al
    The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
    BJU Int. 2024 Sep 10. doi: 10.1111/bju.16493.
    >> Share

  124. VACCARO C, Dewulf K, Richter K, Branger N, et al
    Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique.
    BJU Int. 2024;134:501-503.
    >> Share

  125. ZENNAMI K, Kusaka M, Tomozawa S, Toda F, et al
    Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion.
    BJU Int. 2024;134:426-433.
    >> Share

  126. D'ANDREA D, Soria F, Moschini M, Laukhtina E, et al
    Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy.
    BJU Int. 2024;134:459-464.
    >> Share

  127. AFFERI L, Spahn M, Hayoz S, Strebel RT, et al
    Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
    BJU Int. 2024;134:388-397.
    >> Share

    August 2024
  128. SU ZT, Florissi IS, Mahon KM, Li T, et al
    Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16521.
    >> Share

  129. TAYLOR JI, Kamat AM, O'Donnell MA, Annapureddy D, et al
    Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509.
    >> Share

  130. HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
    Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
    BJU Int. 2024;134:229-238.
    >> Share

  131. MATSUDA A, Taoka R, Miki J, Saito R, et al
    Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
    BJU Int. 2024;134:207-218.
    >> Share

    July 2024
  132. CHAKRA MA, Lassila R, El Beayni N, Mott SL, et al
    Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
    BJU Int. 2024 Jul 31. doi: 10.1111/bju.16486.
    >> Share

  133. REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
    Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
    >> Share

  134. ANTONELLI L, Wendel-Garcia PD, Deforth M, Afferi L, et al
    Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
    BJU Int. 2024 Jul 3. doi: 10.1111/bju.16444.
    >> Share


  135. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int. 2024;134:4-5.
    >> Share

  136. PELLEGRINO F, Scilipoti P, Rosiello G, Longoni M, et al
    Long-term functional outcomes after robot-assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
    BJU Int. 2024;134:48-50.
    >> Share

  137. TUDERTI G, Mastroianni R, Anceschi U, Bove AM, et al
    Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series.
    BJU Int. 2024;134:103-109.
    >> Share

  138. MYERS AA, Tan WS, de Groot J, Westney OL, et al
    'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder.
    BJU Int. 2024;134:45-47.
    >> Share

  139. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
    Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    BJU Int. 2024;134:43-44.
    >> Share

  140. AN X, Xue C, Chen M, Ni M, et al
    Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
    BJU Int. 2024;134:63-71.
    >> Share

    June 2024
  141. WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
    Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
    BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
    >> Share

  142. FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
    Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
    >> Share

  143. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
    How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2024;133:673-677.
    >> Share

    May 2024
  144. FINOCCHIARO A, Paciotti M, Contieri R, Fasulo V, et al
    Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
    BJU Int. 2024 May 22. doi: 10.1111/bju.16406.
    >> Share

  145. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
    Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
    BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
    >> Share

    April 2024
  146. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
    Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
    BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
    >> Share

  147. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
    Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
    BJU Int. 2024 Apr 24. doi: 10.1111/bju.16364.
    >> Share

  148. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
    Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
    >> Share

  149. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
    Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
    >> Share

  150. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
    Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
    >> Share

  151. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
    Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
    BJU Int. 2024;133:474-479.
    >> Share

  152. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
    Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
    BJU Int. 2024;133 Suppl 4:53-63.
    >> Share

  153. BOTROS A, Rival PM, Page F, Davis ID, et al
    Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
    BJU Int. 2024;133 Suppl 4:7-10.
    >> Share

    March 2024
  154. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
    Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
    BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
    >> Share

  155. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
    The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
    >> Share

  156. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
    The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
    >> Share

    February 2024
  157. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
    A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
    >> Share

  158. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
    Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
    >> Share

  159. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    >> Share


  160. Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int. 2024;133:122-123.
    >> Share

  161. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
    Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
    BJU Int. 2024;133:154-157.
    >> Share

    January 2024
  162. LU SM, Zhang Y, Dong XT, Wang JL, et al
    Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
    BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
    >> Share

  163. YIM A, Alberto M, Sharma V, Green A, et al
    Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
    >> Share

    December 2023
  164. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    >> Share

  165. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    >> Share

  166. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    >> Share

    November 2023
  167. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    >> Share

  168. CHEDGY ECP, Tang R, Struss WJ, Lowe G, et al
    A randomized controlled trial investigating rectus sheath catheters following radical cystectomy.
    BJU Int. 2023;132:554-559.
    >> Share

    October 2023
  169. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    >> Share

  170. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    >> Share

  171. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    >> Share

  172. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    >> Share

    September 2023
  173. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    >> Share

    August 2023
  174. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    >> Share

    July 2023
  175. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    >> Share

  176. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    >> Share


  177. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    >> Share

  178. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    >> Share

    June 2023
  179. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    >> Share

  180. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    >> Share

  181. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    >> Share

  182. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    >> Share

    May 2023
  183. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    >> Share

  184. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    >> Share

  185. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    >> Share

    April 2023
  186. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    >> Share

  187. FREGO N, Contieri R, Diana P, Mancon S, et al
    Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
    BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
    >> Share

  188. ROSE KM, Narang G, Rosen G, Labatte C, et al
    Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
    BJU Int. 2023;131:471-476.
    >> Share

  189. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
    Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
    BJU Int. 2023;131:477-485.
    >> Share

    March 2023
  190. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
    Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
    BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
    >> Share

  191. BESIROGLU H
    Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
    BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
    >> Share

  192. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016